Clinical Trial Update: Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of selinexor in combination with pembrolizumab for recurrent advanced melanoma; the study has been terminated a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• XPOVIO (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Locally Advanced Unresectable or Metastatic Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2024-08-23